Hunan ER-KANG Pharmaceutical Co Ltd operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hunan ER-KANG Pharmaceutical Co Ltd with three other
companies in this sector in China:
Shenzhen Hepalink Pharmaceutical Group Co Ltd
sales of 2.67 billion Chinese Renmimbi [US$394.21 million]
of which 100%
was Pharmaceutical Manufacturing),
Zhejiang Jianfeng Group Company Limited
(2.83 billion Chinese Renmimbi [US$417.34 million]
of which 45%
was Cement/Construction Materials), and
Shandong Jincheng Pharmaceutical Group Co Ltd
(2.79 billion Chinese Renmimbi [US$411.65 million]
of which 72%
was Medicine Manufacturing).
Hunan ER-KANG Pharmaceutical Co Ltd reported sales of 2.83 billion Chinese Renmimbi (US$417.54 million)
December of 2017.
decrease of 4.5%
versus 2016, when the company's sales were 2.96 billion Chinese Renmimbi.
Contributing to the drop in overall sales was the 7.8% decline
in Manufacturing of Medicines, from 2.71 billion Chinese Renmimbi to 2.50 billion Chinese Renmimbi.
However, these declines were partially offset by the increase in sales of
Medicine Circulating (up 32.6% to 326.13 million Chinese Renmimbi)